Table 4.
Clinical and laboratory features of patients by pacing modality at baseline and follow-up.
| BiV (n = 13) | HBP (n = 25) | LBBP (n = 10) | p Value—Comparing Groups | |
|---|---|---|---|---|
| NYHA class | ||||
| Initial median NYHA class | 3 | 3 | 3 | 0.175 |
| Nb. in NYHA class 2 | 1 (7.7%) | 2 (8.0%) | 4 (40.0%) | |
| Nb. in NYHA class 3 | 11 (84.6%) | 18 (72.0%) | 5 (50.0%) | |
| Nb. in NYHA class 4 | 1 (7.7%) | 5 (20.0%) | 1 (10.0%) | |
| Follow-up median NYHA class | 3 | 2 | 2 | 0.059 |
| Nb. in NYHA class 1 | 0 | 5 (20.0%) | 4 (40.0%) | |
| Nb. in NYHA class 2 | 6 (46.2%) | 15 (60,0%) | 5 (50.0%) | |
| Nb. in NYHA class 3 | 6 (46.2%) | 5 (20.0%) | 1 (10.0%) | |
| Nb. in NYHA class 4 | 1 (7.7%) | 0 | 0 | |
| p value: initial vs. follow-up | 0.096 | <0.001 | 0.008 | |
| Loop diuretics | ||||
| Initial | 7 (53.8%) | 17 (63.0%) | 7 (70.0%) | 0.8 |
| Follow-up | 6 (46.2%) | 9 (33.3%) | 6 (60.0%) | 0.403 |
| p value: initial vs. follow-up | 0.564 | 0.014 | 0.564 | |
| NT-proBNP [pg/mL] | ||||
| Initial | 1908 (1215–2825) | 2800 (1257–5977) | 2689 (1603–5710) | 0.339 |
| Follow-up | 1856 (1195–2505) | 1472 (904–2113) | 1632 (861–5028) | 0.599 |
| p value: initial vs. follow-up | 0.311 | 0.001 | 0.047 | |
| eGFR [mL/min/1.73 m2] | ||||
| Initial | 58 (51–62) | 52 (45–61) | 66 (35–84) | 0.240 |
| Follow-up | 60 (49–66) | 67 (55–73) | 79 (41–90) | 0.214 |
| p value: initial vs. follow-up | 0.349 | 0.001 | 0.033 | |
BiV: biventricular pacing; HBP: His bundle pacing; LBBP: Left bundle branch pacing; NYHA: New York Heart Association; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; GFR:glomerular filtration rate.